Purine analog antimetabolite

This page covers all Purine analog antimetabolite drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Hypoxanthine-guanine phosphoribosyltransferase (HGPRT), inosine monophosphate dehydrogenase (IMPDH), Ribonucleotide reductase, DNA polymerase, Ribonucleotide reductase; deoxyribonucleotide synthesis pathway.

Targets

Hypoxanthine-guanine phosphoribosyltransferase (HGPRT), inosine monophosphate dehydrogenase (IMPDH) · Ribonucleotide reductase, DNA polymerase · Ribonucleotide reductase; deoxyribonucleotide synthesis pathway · HGPRT (hypoxanthine-guanine phosphoribosyltransferase); inosinate dehydrogenase · Ribonucleotide reductase; DNA polymerase · Purine metabolism enzymes (mercaptopurine); BCR-ABL, c-KIT, PDGFR (imatinib) · Hypoxanthine-guanine phosphoribosyltransferase (HGPRT), thiopurine methyltransferase (TPMT), and purine synthesis pathway enzymes

Marketed (3)

• 6MP · South China Children's Leukemia Group · Oncology
  6MP (6-mercaptopurine) is a purine analog that inhibits nucleotide synthesis and DNA replication, leading to cell death in rapidly dividing cells.
• Fludarabine (Bayer) · Chinese PLA General Hospital · Oncology
  Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to DNA strand breaks and apoptosis in rapidly dividing cells.
• Fludarabine (Flud) · Technische Universität Dresden · Oncology
  Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to disruption of DNA synthesis and cell death in rapidly dividing cells.

Phase 3 pipeline (7)

• Nelarabine injection · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Oncology
  Nelarabine is a prodrug that is converted to arabinosyl guanine, which inhibits ribonucleotide reductase and DNA synthesis, leading to apoptosis in T-cell malignancies.
• Experimental (fludarabine) · French Innovative Leukemia Organisation · Oncology
  Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to DNA strand breaks and apoptosis in rapidly dividing cells.
• Mercaptopurine (Purinethol) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Oncology; Immunology
  Mercaptopurine is a purine analog that inhibits de novo purine synthesis and is converted to active metabolites that interfere with DNA and RNA synthesis, leading to cell death.
• Fludarabine mono · German CLL Study Group · Oncology
  Fludarabine is a purine analog that inhibits DNA synthesis by blocking ribonucleotide reductase and incorporating into DNA, leading to cell death in rapidly dividing lymphocytes.
• Fludarabine Injection · University of California, San Francisco · Oncology
  Fludarabine is a purine analog that inhibits ribonucleotide reductase and DNA polymerase, leading to disruption of DNA synthesis and cell death in rapidly dividing cells.
• Mercaptopurine, Imatinib · St. Jude Children's Research Hospital · Oncology
  Mercaptopurine and imatinib work together as a combination therapy: mercaptopurine is a purine analog that inhibits nucleotide synthesis to kill rapidly dividing cells, while imatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and other oncogenic kinases.
• mercaptopurine tablet · National Cancer Institute (NCI) · Oncology
  Mercaptopurine is a purine analog that inhibits nucleotide synthesis and DNA replication, leading to cell death in rapidly dividing cells.

Patent intelligence

• purine analog antimetabolite patent landscape — aggregated cliff calendar, attackable patents, originator estates